Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › MGNX Leadership & Pay · Jul 8, 2026
Karen Ferrante, M.D., resigned from the Board of Directors of MacroGenics, Inc. effective September 1, 2026 MGNX Macrogenics Inc
Karen Ferrante, M.D., resigned from the Board of Directors of MacroGenics, Inc. effective September 1, 2026. The resignation was for personal reasons and involved no disagreement with the company's operations, policies, or practices. MacroGenics, Inc. is a biotechnology company focused on developing and commercializing therapeutic products.
More from Macrogenics Inc MacroGenics appoints Emil Kuriakose and Michael Vasconcelles to Board of Directors Nov 3, 2026 MacroGenics reports 27% response rate for MGC026 in SCCHN and plans front-line combination study Oct 23, 2026 MacroGenics reported a net income of $19.5 million for the quarter ended June 30, 2026, driven by an $89.2 million… Aug 13, 2026 MacroGenics, Inc. provided a clinical update on its Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate… Jul 23, 2026 On June 30, 2026, MacroGenics, Inc. completed the sale of its GMP manufacturing operations and CDMO business to Bora… Jul 7, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
